Cited by 619COVID-19 Clinical Research StudiesRenin-Angiotensin System StudiesSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Open access

Meng, Juan, Xiao, Guohui, Zhang, Juanjuan, He, Xing, Ou, Min, Bi, Jing, Yang, Rongqing, Di, Wencheng, Wang, Zhaoqin, Li, Zigang, Gao, Hong, Liu, Lei, Zhang, Guoliang·2020·Emerging Microbes & Infections

DOI 10.1080/22221751.2020.1746200PMC PMC7170368

Open this paper in CoChat — free account

Abstract

The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/22221751.2020.1746200

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Summarized clinical, inflammatory, immunological, and viral findings in the non-ACEI/ARB group and the ACE/ARB group. (A) The disease severity distribution of the two groups during hospitalization. (B) The levels of IL-6 and CRP in peripheral blood. (C) Absolute numbers of CD3+, CD4+, and CD8+ T cells in peripheral blood. (D) Viral load on hospital admission and maximum value during hospitalization. The data are expressed as the median and IQR. An unpaired t test was used, and P < 0.05 was considered significant.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citation
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Self-citation
Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury
Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng, C., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1643-8 · Cited by 2,056
Self-citation
Status of Hypertension in China: Results From the China Hypertension Survey, 2012–2015
Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., Shao, L., Tian, Y., Dong, Y., Zheng, C., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032380 · Cited by 1,698
Self-citation
Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2951-z · Cited by 715
Self-citation
Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury
Yang, P., Gu, H., Zhao, Z., Wang, W., Cao, B., Lai, C., Yang, X., Zhang, L., Duan, Y., Zhang, S., et al. (2014) · Scientific Reports · doi:10.1038/srep07027 · Cited by 283
ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway
Ye, R., & Liu, Z. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104350 · Cited by 205
Beta Blocker and Angiotensin-Converting Enzyme Inhibitor Therapy Is Associated with Decreased Th1/Th2 Cytokine Ratios and Inflammatory Cytokine Production in Patients with Chronic Heart Failure
Gage, J. R., Fonarow, G. C., Hamilton, M. A., Widawski, M., Martı́nez-Maza, O., & Vredevoe, D. L. (2004) · NeuroImmunoModulation · doi:10.1159/000076766 · Cited by 81
Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
Moon, J.-Y. (2013) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2013.11.2.41 · Cited by 81

Show all 14 references

Research works printed but not linked: 1

Moon JY. Recent Update of renin-angiotensin-aldosterone. Sys Pathogenesis Hypertens. 2013;11(2):41–45.

Sorted by citations

Items 101–200 of 619

Influence of blood pressure control and application of renin‐angiotensin‐aldosterone system inhibitors on the outcomes in COVID‐19 patients with hypertension
Chen, R., Yang, J., Gao, X., Ding, X., Yang, Y., Shen, Y., He, C., Xiang, H., Ke, J., Yuan, F., et al. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14038 · Cited by 62
A Review on the Neurological Manifestations of COVID-19 Infection: a Mechanistic View
Zangbar, H. S., Gorji, A., & Ghadiri, T. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02149-0 · Cited by 57
Drug repurposing and cytokine management in response to COVID-19: A review
Heimfarth, L., Serafini, M. R., Martins‐Filho, P. R., Quintans, J. D. S. S., & Quintans‐Júnior, L. J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106947 · Cited by 55
Use of inhibitors of the renin‐angiotensin system in hypertensive patients and COVID‐19 severity: A systematic review and meta‐analysis
Barochiner, J., & Martínez, R. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13246 · Cited by 56
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients
Trifirò, G., Massari, M., Cas, R. D., Menniti‐Ippolito, F., Sultana, J., Crisafulli, S., Rossi, P. G., Marino, M., Zorzi, M., Bovo, E., et al. (2020) · Drug Safety · doi:10.1007/s40264-020-00994-5 · Cited by 55
Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation
Augustine, R., Abhilash, S., Nayeem, A., Salam, S. A., Augustine, P., Dan, P., Maureira, P., Mraiche, F., Gentile, C., Hansbro, P. M., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109738 · Cited by 55
Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study
Matsuzawa, Y., Ogawa, H., Kimura, K., Konishi, M., Kirigaya, J., Fukui, K., Tsukahara, K., Shimizu, H., Iwabuchi, K., Yamada, Y., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-00535-8 · Cited by 52
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system
Herman‐Edelstein, M., Guetta, T., Barnea, A., Waldman, M., Ben-Dor, N., Barac, Y. D., Kornowski, R., Arad, M., Hochhauser, E., & Aravot, D. J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01275-w · Cited by 52
Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis
Ssentongo, A. E., Ssentongo, P., Heilbrunn, E. S., Lekoubou, A., Du, P., Liao, D., Oh, J. S., & Chinchilli, V. M. (2020) · Open Heart · doi:10.1136/openhrt-2020-001353 · Cited by 51
Coronavirus and Cardiometabolic Syndrome
Mechanick, J. I., Rosenson, R. S., Pinney, S., MANCINI, D. M., Narula, J., & Fuster, V. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.069 · Cited by 51
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
Akhtar, S., Benter, I. F., Danjuma, M. I.-M., Doi, S. A. R., Hasan, S. S., & Habib, A. M. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1797754 · Cited by 49
The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients
Zamai, L. (2020) · Cells · doi:10.3390/cells9071704 · Cited by 47
Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19
Soleimani, A., Kazemian, S., Saleh, S. K., Aminorroaya, A., Shajari, Z., Hadadi, A., Talebpour, M., Sadeghian, H., Payandemehr, P., Sotoodehnia, M., et al. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa149 · Cited by 47
RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies
Castelnuovo, A. F. D., Costanzo, S., Antinori, A., Berselli, N., Blandi, L., Bonaccio, M., Cauda, R., Gialluisi, A., Guaraldi, G., Menicanti, L., et al. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106805 · Cited by 46
COVID-19 and hypertension
Kulkarni, S., Jenner, B., & Wilkinson, I. B. (2020) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320320927851 · Cited by 47
Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
Patoulias, D., Katsimardou, A., Stavropoulos, K., Imprialos, K. P., Kalogirou, M., & Doumas, M. N. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01101-w · Cited by 47
COVID-19 and the World with Co-Morbidities of Heart Disease, Hypertension and Diabetes
Anand, A. V., Sangeetha, T., Fathah, Z., Pavithra, R., Sanjeev, A. M. A., Babu, S., Meyyazhagan, A., Yatoo, M. I., Sharun, K., Tiwari, R., et al. (2020) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.14.3.01 · Cited by 46
Endocrine Conditions and COVID-19
Shekhar, S., Wurth, R., Kamilaris, C. D. C., Eisenhofer, G., Barrera, F. J., Hajdenberg, M., Tonleu, J. T., Hall, J. E., Schiffrin, E. L., Porter, F. D., et al. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1172-1352 · Cited by 45
COVID-19 in patients with heart failure: the new and the old epidemic
Sisti, N., Valente, S., Mandoli, G. E., Santoro, C., Sciaccaluga, C., Franchi, F., Cameli, P., Mondillo, S., & Cameli, M. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138080 · Cited by 44
Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment
Luo, J., Zhu, X., Jian, J., Chen, X., & Yin, K. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa176 · Cited by 45
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Vieira, C. C., Nery, L., Martins, L. D. B. U., Jabour, L. G. P. P., Dias, R. F., & Silva, A. C. S. E. (2020) · Current Drug Targets · doi:10.2174/1389450121666201020154033 · Cited by 46
Do Changes in ACE-2 Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms
Yalcin, H. C., Sukumaran, V., Al-Ruweidi, M. K. A. A., & Shurbaji, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136703 · Cited by 51
Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review
Mascolo, A., Scavone, C., Rafaniello, C., Ferrajolo, C., Racagni, G., Berrino, L., Paolisso, G., Rossi, F., & Capuano, A. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00143 · Cited by 42
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor
Öz, M., Lorke, D. E., & Kabbani, N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107750 · Cited by 45
Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain
Vila-Córcoles, Á., Gondar, O. O., Satué-Gracia, E. M., Torrente‐Fraga, C., Gómez-Bertomeu, F., Vila-Rovira, Á., de Diego‐Cabanes, C., Bejarano‐Romero, F., & Basora, J. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-041577 · Cited by 43
Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19
Shete, A. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.05.002 · Cited by 43
Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2
Ridgway, H. F., Moore, G. J., Mavromoustakos, T., Tsiodras, S., Ligielli, I., Kelaidonis, K., Chasapis, C. T., Gadanec, L. K., Zulli, A., Apostolopoulos, V., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.010 · Cited by 44
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
Xu, J., Huang, C., Fan, G., Liu, Z., Shang, L., Zhou, F., Wang, Y., Yu, J., Yang, L., Xie, K., et al. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0800-y · Cited by 42
Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen
Mirjalili, M., Shafiekhani, M., & Vazin, A. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s256246 · Cited by 42
Two hits to the renin‐angiotensin system may play a key role in severe COVID ‐19
Tseng, Y., Yang, R., & Lu, T. (2020) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12237 · Cited by 41
Self-citation
Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis
Sfera, A., Osorio, C., Jafri, N., Diaz, E. L., & Maldonado, J. E. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01472 · Cited by 42
Review of registered clinical trials for the treatment of COVID‐19
Babaei, F., Mirzababaei, M., Nassiri‐Asl, M., & Hosseinzadeh, H. (2020) · Drug Development Research · doi:10.1002/ddr.21762 · Cited by 43
Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis
Hasan, S. S., Kow, C. S., Hadi, M. A., Zaidi, S. T. R., & Merchant, H. A. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00439-5 · Cited by 45
Comparison of losartan and amlodipine effects on the outcomes of patient with COVID‐19 and primary hypertension: A randomised clinical trial
Nouri‐Vaskeh, M., Kalami, N., Zand, R., Soroureddin, Z., Varshochi, M., Ansarin, K., Rezaee, H., Taghizadieh, A., Sadeghi, A., Maleki, M., et al. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14124 · Cited by 41
COVID-19: the endocrine opportunity in a pandemic
Chatterjee, S., Ghosh, R., Biswas, P., Dubey, S., Guria, R. T., Sharma, C. B., & Kalra, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03216-2 · Cited by 41
Drugs against SARS‐CoV ‐2: What do we know about their mode of action?
Valle, C., Martin, B., Touret, F., Shannon, A., Canard, B., Guillemot, J., Coutard, B., & Decroly, É. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2143 · Cited by 42
Commonalities Between COVID-19 and Radiation Injury
Rios, C. I., Cassatt, D. R., Hollingsworth, B. A., Satyamitra, M. M., Tadesse, Y., Taliaferro, L. P., Winters, T. A., & DiCarlo, A. L. (2020) · Radiation Research · doi:10.1667/rade-20-00188.1 · Cited by 43
ACE inhibitors and COVID‐19: We don't know yet
Khashkhusha, T. R., Chan, J. S. K., & Harky, A. (2020) · Journal of Cardiac Surgery · doi:10.1111/jocs.14582 · Cited by 41
Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis
Lee, M. M. Y., Docherty, K. F., Sattar, N. A., Mehta, N., Kalra, A., Nowacki, A. S., Solomon, S. D., Vaduganathan, M., Petrie, M. C., Jhund, P. S., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa138 · Cited by 41
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19
Furuhashi, M., Moniwa, N., Takizawa, H., Ura, N., & Shimamoto, K. (2020) · Hypertension Research · doi:10.1038/s41440-020-0478-1 · Cited by 44
COVID-19, Angiotensin Receptor Blockers, and the Brain
Saavedra, J. M. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00861-y · Cited by 40
Neurological Impact of Coronavirus Disease of 2019: Practical Considerations for the Neuroscience Community
Werner, C., Scullen, T. A., Mathkour, M., Zeoli, T. C., Beighley, A., Kilgore, M. D., Carr, C., Zweifler, R. M., Aysenne, A. M., Maulucci, C. M., et al. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.04.222 · Cited by 40
Candesartan could ameliorate the COVID-19 cytokine storm
ELKAHLOUN, A. G., & Saavedra, J. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110653 · Cited by 40
Therapeutic Strategies for SARS-CoV-2 acting on ACE-2
Vitiello, A., & Ferrara, F. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105579 · Cited by 38
Coronary heart disease and COVID-19: A meta-analysis
Liang, C., Zhang, W., Li, S., & Qin, G. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.12.021 · Cited by 38
Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
Singh, R., Rathore, S. S., Khan, H., Bhurwal, A., Sheraton, M., Ghosh, P., Anand, S., Makadia, J., Ayesha, F., Mahapure, K. S., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.703661 · Cited by 38
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore
Saavedra, J. M. (2021) · Physiology · doi:10.1152/physiol.00036.2020 · Cited by 37
Covid-19: Aspectos da origem, fisiopatologia, imunologia e tratamento - uma revisão narrativa
Silva, C. C. D., Carvalho, C. M. O. D., Lima, D. C. D., Costa, E. S., de Andrade, V. M. B., Tenório, B. M., Britto, D. B. L. D. A., & Tenório, F. D. C. Â. M. (2021) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e6542.2021 · Cited by 37
Snake venom‐derived bradykinin‐potentiating peptides: A promising therapy for COVID ‐19?
Gouda, A. S., & Mégarbane, B. (2020) · Drug Development Research · doi:10.1002/ddr.21732 · Cited by 37
Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis
Chu, C., Zeng, S., Hasan, A. A., Hocher, C., Krämer, B. K., & Hocher, B. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14660 · Cited by 36
Potential benefits of dietary seaweeds as protection against COVID-19
Tamama, K. (2020) · Nutrition Reviews · doi:10.1093/nutrit/nuaa126 · Cited by 40
Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry
López‐Otero, D., López‐País, J., Antonio, C. E. C., Muiños, P. J. A., González-Ferrero, T., Pérez-Poza, M., García, Ó. O., Díaz‐Fernández, B., Bastos-Fernández, M., Bouzas‐Cruz, N., et al. (2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.018 · Cited by 35
The burden of type 2 diabetes pre-and during the COVID-19 pandemic – a review
Sciberras, J., Camilleri, L. M., & Cuschieri, S. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00656-4 · Cited by 37
Therapeutic approaches targeting renin-angiotensin system in sepsis and its complications
Ning, L., Rong, J., Zhang, Z., & Xu, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105409 · Cited by 36
Triangle of cytokine storm, central nervous system involvement, and viral infection in COVID-19: the role of sFasL and neuropilin-1
Saleki, K., Banazadeh, M., Miri, N. S., & Azadmehr, A. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0047 · Cited by 37
RAAS, ACE2 and COVID-19; a mechanistic review
Elshafei, A., Khidr, E. G., El-Husseiny, A. A., & Gomaa, M. H. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.07.003 · Cited by 37
Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy
Ridgway, H. F., Chasapis, C. T., Kelaidonis, K., Ligielli, I., Moore, G. J., Gadanec, L. K., Zulli, A., Apostolopoulos, V., Mavromoustakos, T., & Matsoukas, J. (2022) · Viruses · doi:10.3390/v14051029 · Cited by 35
Drugs acting on the renin–angiotensin system and SARS-CoV-2
Vitiello, A., Pelliccia, C., & Ferrara, F. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.010 · Cited by 35
Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options
Huang, B., Ling, R., Cheng, Y., Wen, J., Dai, Y., Huang, W., Zhang, S., Lu, X., Luo, Y., & Jiang, Y.-Z. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.013 · Cited by 38
COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
Doumas, M. N., Patoulias, D., Katsimardou, A., Stavropoulos, K., Imprialos, K. P., & Karagiannis, A. I. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0380-y · Cited by 35
Blocking TNF signaling may save lives in COVID-19 infection
Ablamunits, V. G., & Lepsy, C. S. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07166-x · Cited by 34
Thymus vulgaris, a natural pharmacy against COVID-19: A molecular review
Nadi, A., Shiravi, A. A., Mohammadi, Z. S., Amin, A., & Zeinalian, M. (2023) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2023.100635 · Cited by 36
Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint
Cappuccio, F. P., & Siani, A. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.013 · Cited by 36
Might renin–angiotensin system blockers play a role in the COVID-19 pandemic?
Battistoni, A., & Volpe, M. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa030 · Cited by 33
SARS-CoV-2/Renin–Angiotensin System: Deciphering the Clues for a Couple with Potentially Harmful Effects on Skeletal Muscle
González, A., Orozco-Aguilar, J., Achiardi, O. A., Simón, F., & Cabello‐Verrugio, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217904 · Cited by 35
Targeting the renin−angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges
Sriram, K., Loomba, R. S., & Insel, P. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009875117 · Cited by 33
Factors associated with clinical severity in emergency department patients presenting with symptomatic SARS‐CoV‐2 infection
Newton, S., Zollinger, B., Freeman, J. Q., Moran, S., Helfand, A., Authelet, K. J., McHarg, M., Vargas, N. M., Shesser, R. F., Cohen, J. S., et al. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12453 · Cited by 33
Layer-by-Layer Coating of Single-Cell Lacticaseibacillus rhamnosus to Increase Viability Under Simulated Gastrointestinal Conditions and Use in Film Formation
Sbehat, M., Altamimi, M., Sabbah, M., & Mauriello, G. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.838416 · Cited by 32
Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein
Feng, S., Luan, X., Wang, Y., Wang, H., Zhang, Z., Wang, Y., Tian, Z., Liu, M., Xiao, Y., Zhao, Y., et al. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104419 · Cited by 33
Renin-angiotensin system at the interface of COVID-19 infection
Gul, R., Kim, U., & Alfadda, A. A. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173656 · Cited by 31
Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19
Issa, H., Eid, A. H., Berry, B., Takhviji, V., Khosravi, A., Mantash, S., Nehme, R., Hallal, R., Karaki, H., Dhayni, K., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.620990 · Cited by 30
Correction to: Expression of the SARS‑CoV‑2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system
Herman‐Edelstein, M., Guetta, T., Barnea, A., Waldman, M., Ben-Dor, N., Barac, Y. D., Kornowski, R., Arad, M., Hochhauser, E., & Aravot, D. J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01402-7 · Cited by 32
Outcomes Associated with the Use of Renin-Angiotensin-Aldosterone System Blockade in Hospitalized Patients with SARS-CoV-2 Infection
Chaudhri, I., Koraishy, F. M., Bolotova, O., Yoo, J., Marcos, L. A., Taub, E. M., Sahib, H., Bloom, M. W., Ahmad, S., Skopicki, H. A., et al. (2020) · Kidney360 · doi:10.34067/kid.0003792020 · Cited by 31
Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020
Nabil, A., Uto, K., Elshemy, M. M., Soliman, R., Hassan, A., Ebara, M., & Shiha, G. E.-S. (2020) · EXCLI journal · doi:10.17179/excli2020-2554 · Cited by 31
Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study
AlGhatrif, M., Tanaka, T., Moore, A. Z., Bandinelli, S., Lakatta, E. G., & Ferrucci, L. (2021) · GeroScience · doi:10.1007/s11357-020-00314-w · Cited by 31
Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review
Sharifi, Y., Payab, M., Mohammadi‐Vajari, E., Aghili, S. M. M., Sharifi, F., Mehrdad, N., Kashani, E., Shadman, Z., Larijani, B. A., & Ebrahimpur, M. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00822-2 · Cited by 32
Host factors facilitating SARS‐CoV‐2 virus infection and replication in the lungs
Boutin, S., Hildebrand, D., Boulant, S., Kreuter, M., Rüter, J., Pallerla, S. R., Velavan, T. P., & Nurjadi, D. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03889-5 · Cited by 32
Outcomes and implications of diarrhea in patients with SARS-CoV-2 infection
Shang, H., Bai, T., Chen, Y., Huang, C., Zhang, S., Yang, P., Zhang, L., & Hou, X. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1800078 · Cited by 30
COVID-19 Usurps Host Regulatory Networks
Curran, C. S., Rivera, D. R. R., & Kopp, J. B. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01278 · Cited by 31
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis
Lo, K. B., Bhargav, R., Salacup, G., Pelayo, J., Albano, J., McCullough, P. A., & Rangaswami, J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1826308 · Cited by 32
Single-Cell Transcriptome Analysis Decipher New Potential Regulation Mechanism of ACE2 and NPs Signaling Among Heart Failure Patients Infected With SARS-CoV-2
Ma, M., Xu, Y., Su, Y., Ong, S., Hu, X., Chai, M., Zhao, M., Li, H., Fan, X., Chen, Y., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.628885 · Cited by 29
Mortality and Pre‐Hospitalization Use of Renin‐Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID‐19)
Chen, C., Wang, F., Chen, P., Jiang, J., Cui, G., Zhou, N., Moroni, F., Moslehi, J. J., Ammirati, E., & Wang, D. W. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017736 · Cited by 41
Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection
Spagnolello, O., Pinacchio, C., Santinelli, L., Vassalini, P., Innocenti, G. P., Girolamo, G. D., Fabris, S., Giovanetti, M., Angeletti, S., Russo, A., et al. (2021) · Chemotherapy · doi:10.1159/000515344 · Cited by 29
Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics
Liu, D., Liu, J., Liang, S., Meng, X., Greenbaum, J., Xiao, H., Tan, L., & Deng, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040545 · Cited by 32
COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
Xie, L., Zhang, Z., Wang, Q., Chen, Y., Lu, D., & Wu, W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.772865 · Cited by 30
COVID-19 and the Renin Angiotensin System: Implications for the Older Adults
Bahat, G. (2020) · The journal of nutrition health & aging · doi:10.1007/s12603-020-1403-7 · Cited by 29
Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension
Nuche, J., de la Cal, T. S., López-Guarch, C. J., López‐Medrano, F., Delgado, C. P.-O., Arribas, F., Delgado, J. F., Ibáñez, B., Oliver, E., & Subías, P. E. (2020) · Diagnostics · doi:10.3390/diagnostics10080548 · Cited by 28
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?
Jakovac, H. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00506.2020 · Cited by 28
Managing hypertension during the COVID-19 pandemic
Nadar, S. K., Tayebjee, M. H., Stowasser, M., & Byrd, J. B. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0356-y · Cited by 28
COVID‐19: Risk groups, mechanistic insights and challenges
Stein, R. A. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13512 · Cited by 32
Covid-19 and drug therapy, what we learned
Provenzani, A., & Polidori, P. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01049-6 · Cited by 27
Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure
Razeghian‐Jahromi, I., Zibaeenezhad, M. J., Lu, Z., Elyaspour, Z., Razmkhah, M., & Lionetti, V. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10016-2 · Cited by 29
ACEIs and ARBs and Their Correlation with COVID-19: A Review
Yehualashet, A. S., & Belachew, T. F. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s264882 · Cited by 29
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19
Usman, M., Siddiqi, T. J., Khan, M. S., Ahmed, A., Ali, S. S., Michos, E. D., Hall, M. E., Krasuski, R. A., Greene, S. J., Butler, J., et al. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.05.038 · Cited by 28
A call to action becomes practice: cardiac and vascular surgery during the COVID-19 pandemic based on the Lombardy emergency guidelines
Bonalumi, G., Giambuzzi, I., Barbone, A., Ranieri, C., Cavallotti, L., Trabattoni, P., Naliato, M., Polvani, G., Torracca, L., Pelenghi, S., et al. (2020) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaa204 · Cited by 26
Is Sex a Determinant of COVID-19 Infection? Truth or Myth?
Groban, L., Wang, H., Sun, X., Ahmad, S., & Ferrario, C. M. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01073-x · Cited by 27
The impact of COVID-19 on health status of home-dwelling elderly patients with dementia in East Lombardy, Italy: results from COVIDEM network
Caratozzolo, S., Zucchelli, A., Turla, M., Cotelli, M. S., Fascendini, S., Zanni, M., Bianchetti, A., Psy, M. P., Rozzini, R., Boffelli, S., et al. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01676-z · Cited by 25
Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits
Banerjee, A., Ganguly, U., Saha, S., Chakrabarti, S., Saini, R. V., Rawal, R. K., Saso, L., & Chakrabarti, S. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1905519 · Cited by 27
Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019
Swiderski, J., Gadanec, L. K., Apostolopoulos, V., Moore, G. J., Kelaidonis, K., Matsoukas, J., & Zulli, A. (2023) · Biomolecules · doi:10.3390/biom13050787 · Cited by 27
The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
Zhang, J., Wang, M., Ding, W., & Wan, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118142 · Cited by 25
Self-citation

Authors: Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., Yang, R., Di, W., Wang, Z., Li, Z., Gao, H., Liu, L., & Zhang, G.
Affiliations: Southern University of Science and Technology (CN)
Shenzhen Bay Laboratory (CN)
Corresponding author: Gao, Hong
Liu, Lei
Zhang, Guoliang
ORCID: Xiao, Guohui
Zhang, Juanjuan
He, Xing
Ou, Min
Bi, Jing
Wang, Zhaoqin
Li, Zigang
Gao, Hong
Liu, Lei
Zhang, Guoliang
Venue: Emerging Microbes & Infections
Publisher: Informa UK Limited
Published: 2020-01
Volume: 9
Issue: 1
Pages: 757-760
ISSN: 2222-1751 (ISSN-L)
DOI: 10.1080/22221751.2020.1746200
PMC: PMC7170368
OpenAlex: W3013871850
Cited by: 619
References: 14
Citations by year: 2026: 3 · 2025: 9 · 2024: 22 · 2023: 31 · 2022: 61 · 2021: 194 · 2020: 297
FWCI: 19.12
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Emerging Microbes & Infections (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
ImmPort
Funders: National Natural Science Foundation of China (81873958)
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords: COVID-19 pandemic, hypertension, renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, SARS-CoV-2, interleukin-6, T-cell count, viral load, antihypertensive therapy
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, C-Reactive Protein, China, Female, Humans, Hypertension, Male, Middle Aged, Pneumonia, Viral, Renin-Angiotensin System, Retrospective Studies, Interleukin-6, Treatment Outcome, CD3 Complex, Coronavirus Infections, CD8-Positive T-Lymphocytes, Viral Load, Angiotensin II Type 1 Receptor Blockers, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks